Clinical Trial Search

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 44.8; 39.2; 18.1 Percentage of patients…

Primary: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From…

Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…

Primary: Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24 — 33.6; 45.7; 12.3 Percentage of patients…

Primary: Percentage Change in Retinal Thickness in the Study Eye at 6 Months Compared to Baseline — -7.89 percentage change in retinal thickness

Primary: Macular Thickness at 3 Days After Intravitreous Dexamethasone — 438.44; 465.22; 368.22 µm

Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters

Primary: Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline. — 3; 18 participants

Primary: Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME) — 1.72; 1.69 months per participant — p=0.969

Primary: Change in Central Subfield Thickening From Baseline Through 34 Weeks — -10; -47; -27; -16 microns — p=0.46

Primary: Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline — 69.95; 74 letters

Primary: Visual Acuity — 52 Units on a scale

Primary: Mean Change in Best Corrected Visual Acuity — 0.3; 0.33 logMAR units

Primary: Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters…

Primary: Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12 — 62.3; 64.1; 65.1; 68.25 Letters

Primary: Change in Central Retinal Thickness (CRT) — 384.62; 374; 349.15; 357.62 micrometer

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts. — 0.18; 0.36; 0.18 logMAR

Primary: Incidence of Ocular and Non-Ocular Adverse Events (AEs) — 10; 8 participants

Primary: Rates of Retina Care Referral for Patients With Diabetic Macular Edema — 44 Participants

Primary: Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years. — 1; -2; -3 Letter score — p=0.02

Primary: Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline) — 5.7; 5.9; 1.4 Letters

Primary: Best Corrected Visual Acuity as Measured by ETDRS at 6 and 12 Months — 78; 73.92; 77.92; 74.83 letters read correctly

Primary: Frequency (Number) of Ocular and Non-ocular Treatment Emergent Adverse Events (TEAE). — 36.5; 60; 40; 21.2 Percentage of participants

Primary: Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline — 58.8; 67.6; 8.8 letters

Primary: The Change in Visual Acuity (Number of ETDRS Letters). — 67.8; 71.9; 69.6; 72.9 ETDRS letters

Primary: Number of Participants With Ocular and Non-Ocular Adverse Events — 11; 10; 5; 3 Participants

Primary: FAZ Area Change — 0.03 mm^2